|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/03/22 Sarepta Therapeutics, Inc. 8-K:5,9 6/02/22 11:250K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 49K 2: EX-10.1 Material Contract HTML 11K 6: R1 Document And Entity Information HTML 46K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- srpt-20220602_htm XML 15K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 5: EX-101.LAB XBRL Labels -- srpt-20220602_lab XML 40K 4: EX-101.PRE XBRL Presentations -- srpt-20220602_pre XML 31K 3: EX-101.SCH XBRL Schema -- srpt-20220602 XSD 11K 10: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K 11: ZIP XBRL Zipped Folder -- 0000950170-22-011164-xbrl Zip 13K
| 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i June 02, 2022 |
i Sarepta Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
i Delaware |
i 93-0797222 |
|||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
i 215 First Street |
|
|||
i Cambridge, i Massachusetts |
|
i 02142 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: i (617) i 274-4000 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
i Common Stock, $0.0001 par value per share |
|
i SRPT |
|
i NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 2, 2022, Sarepta Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted to approve an amendment (the “2018 Plan Amendment”) to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan Amendment increases the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 10,687,596 shares (plus the number of shares subject to outstanding awards under the Company’s Amended and Restated 2011 Equity Incentive Plan that expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by the Company (up to a maximum of 2,412,466 shares)). The foregoing summary of the 2018 Plan Amendment is qualified in its entirety by reference to the full text of the 2018 Plan Amendment, which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each such proposal. As of the record date for the Annual Meeting, April 8, 2022, there were 87,497,505 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 75,064,175 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 85.79% of the outstanding shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business.
Proposal 1: Election of Directors
The director nominees listed below were elected to serve on the Company’s board of directors as members of Class I for a term of two years. The results of the vote were as follows:
Name of Nominee |
|
For |
|
|
|
|
Against |
|
|
|
Abstain |
|
|
|
Broker Non- |
|
Kathryn Boor, Ph.D. |
|
67,109,976 |
|
|
|
|
134,940 |
|
|
|
27,270 |
|
|
|
7,791,989 |
|
Michael Chambers |
|
67,104,537 |
|
|
|
|
138,475 |
|
|
|
29,174 |
|
|
|
7,791,989 |
|
|
66,697,111 |
|
|
|
|
546,004 |
|
|
|
29,071 |
|
|
|
7,791,989 |
|
|
Hans Wigzell, M.D., Ph.D. |
|
63,849,134 |
|
|
|
|
3,396,295 |
|
|
|
26,757 |
|
|
|
7,791,989 |
|
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation
The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2021. The results of the advisory vote were as follows:
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
62,746,933 |
|
4,465,735 |
|
59,518 |
|
7,791,989 |
Proposal 3: Amendment to the Company’s 2018 Equity Incentive Plan
The stockholders approved the 2018 Plan Amendment. The results of the vote were as follows:
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
62,644,364 |
|
4,572,292 |
|
55,530 |
|
7,791,989 |
Proposal 4: Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm
The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2022. The results of the vote were as follows:
For |
|
Against |
|
Abstain |
73,729,807 |
|
1,244,784 |
|
89,584 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Description |
10.1 |
|
Amendment No. 2 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan |
104 |
|
The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Sarepta Therapeutics, Inc. |
|
|
|
|
|
Date: June 3, 2022 |
|
By: |
|
|
|
|
|
|
|
|
President and Chief Executive Officer |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/22 | ||||
| Filed on: | 6/3/22 | 4 | ||
| For Period end: | 6/2/22 | 3, 4, DEF 14A | ||
| 4/8/22 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 2/28/24 Sarepta Therapeutics, Inc. 10-K 12/31/23 119:18M Donnelley … Solutions/FA 8/02/23 Sarepta Therapeutics, Inc. S-8 8/02/23 4:69K Donnelley … Solutions/FA 2/28/23 Sarepta Therapeutics, Inc. 10-K 12/31/22 119:23M Donnelley … Solutions/FA 8/02/22 Sarepta Therapeutics, Inc. S-8 8/02/22 4:58K Donnelley … Solutions/FA 8/02/22 Sarepta Therapeutics, Inc. 10-Q 6/30/22 79:11M Donnelley … Solutions/FA |